Schroder Investment Management Group
PCVX icon

Schroder Investment Management Group’s Vaxcyte PCVX Stock Holding History

Schroder Investment Management Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-80,238
Closed -$2.78M – 1199
2025
Q3 		$2.78M Buy
80,238
+1,112
+1% +$36.8K ﹤0.01% 870
2025
Q2 		$2.57M Buy
79,126
+13,010
+20% +$426K ﹤0.01% 878
2025
Q1 		$4.59M Buy
66,116
+21,298
+48% +$1.7M ﹤0.01% 770
2024
Q4 		$3.67M Buy
44,818
+30,444
+212% +$3.02M ﹤0.01% 829
2024
Q3 		$1.63M Hold
14,374
– – ﹤0.01% 967
2024
Q2 		$1.09M Hold
14,374
– – ﹤0.01% 1017
2024
Q1 		$982K Buy
+14,374
New +$995K ﹤0.01% 1030

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Schroder Investment Management Group's PCVX Position: Q4 2025 in Review

Schroder Investment Management Group sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 80,238 shares — an estimated $2.78M sold.

Schroder Investment Management Group first reported a position in PCVX in Q1 2024 and held it in 7 quarters. The position peaked at $4.59M in Q1 2025. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

  • Schroder Investment Management Group reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 80,238 Vaxcyte shares in Q4 2025, an estimated $2.78M.
  • Schroder Investment Management Group first reported a position in Vaxcyte in Q1 2024 and held it in 7 quarters.
  • Schroder Investment Management Group's Vaxcyte position peaked at $4.59M in Q1 2025.
  • 295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.